Cytaright 500mg Injection

• Acute myeloid leukemia (AML)
• Chronic myelogenous leukemia (CML)
• Meningeal leukaemia

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Cytaright 500mg Injection also causes some adverse impact on the body, most of which resolve without any medical attention. Some common side effects include:

• Rash
• Skin ulcer
• Nausea
• Vomiting
• Hair loss
• Abdominal pain
• Anal ulcers
• Anemia (low number of red blood cells)
• Decreased white blood cell count
• Fever
• Infection
• Abnormal liver function
• Low blood platelets
• Mouth ulcer
• Pneumonia
• Sepsis
• Mouth sore
• Stomatitis (Inflammation of the mouth)

Seek medical attention in case of any unusual or severe side effects immediately.

• Cytaright 500mg is available in injection form and is advised to be taken as per the doctor's prescription. It can be given under the skin (subcutaneous) into a vein (intravenously) into a muscle (intramuscularly) or the spine (intrathecal) by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  
  

• Cytaright 500mg Injection is a cytotoxic drug that contains Cytarabine as an active ingredient. It works by primarily killing cancer cells by interfering with their DNA synthesis.
• It causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death. Results in slowing or stopping the growth of cancer cells in your body. 

• Dillman, R. O., Davis, R. B., Green, M. R., Weiss, R. B., Gottlieb, A. J., Caplan, S., ... & Schiffer, C. (1991). A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. https://pubmed.ncbi.nlm.nih.gov/1824249/
• Wiernik, P. H., Banks, P. L., Case, D. J., Arlin, Z. A., Periman, P. O., Todd, M. B., ... & Weitberg, A. B. (1992). Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. https://pubmed.ncbi.nlm.nih.gov/1730080/
• Murphy, T., & Yee, K. W. (2017). Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert opinion on pharmacotherapy, 18(16), 1765-1780. https://pubmed.ncbi.nlm.nih.gov/29017371/
  
• Momparler, R. L. (2013). Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. Experimental hematology & oncology, 2(1), 20. https://pubmed.ncbi.nlm.nih.gov/23919448/
• Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., ... & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027-1036. https://pubmed.ncbi.nlm.nih.gov/21410371/